Rare Diseases
Soligenix Gains EU Orphan Drug Designation for SGX945 in Behçet's Disease, Bolstering Rare Disease Pipeline
The European Commission granted orphan drug designation to Soligenix's SGX945 for Behçet's disease, validating the therapy's potential and supporting the company's rare disease strategy.
Soligenix CEO Advocates for Patient-Centric Reformulation Strategy in Rare Disease Drug Development
Soligenix CEO Christopher Schaber argues that reformulating therapies to better fit patients' daily lives can improve access, adherence, and long-term viability, highlighting a strategic shift in biopharmaceutical development.
Soligenix Gains European Orphan Drug Designation for Behçet's Disease Therapy SGX945
The European Commission granted orphan drug designation to Soligenix's SGX945 for treating Behçet's disease, validating the therapy's potential and providing regulatory and commercial incentives for development in a rare disease area with significant unmet need.
Soligenix Secures Financial Stability Through 2026 to Advance Rare Disease and Biodefense Pipeline
Soligenix has strengthened its financial position with strategic capital initiatives, providing runway through 2026 to advance multiple late-stage therapeutic and vaccine candidates addressing rare diseases and biodefense needs.
Tonix Pharmaceuticals Advances TNX-2900 for Prader-Willi Syndrome Into Phase 2 Clinical Trial
Tonix Pharmaceuticals has received FDA clearance to begin Phase 2 trials for TNX-2900, a potential treatment for Prader-Willi syndrome, marking significant progress for a rare genetic disorder that causes life-threatening childhood obesity.
Soligenix Appoints Former White House Economic Advisor Tomas Philipson to Guide Rare Disease Drug Development
Soligenix's appointment of healthcare policy expert Tomas Philipson signals strategic positioning to navigate regulatory pathways for its lead rare disease treatment HyBryte™, potentially accelerating market access for unmet medical needs.
Oncotelic Therapeutics Reports Two Years of Clinical Progress Across Oncology and Rare Disease Programs
Oncotelic Therapeutics has achieved significant clinical milestones over the past two years, advancing multiple late-stage programs including OT-101 for pancreatic cancer and OXi4503 for AML/MDS, positioning the company to address multi-billion-dollar markets with high unmet medical needs.
Zevra Therapeutics to Present New MIPLYFFA Data at International Congress, Including Best Poster Award Winner
Zevra Therapeutics will present four posters on MIPLYFFA (arimoclomol) at the International Congress of Inborn Errors of Metabolism, including a Best Poster award-winning presentation detailing its mechanism of action for treating Niemann-Pick disease type C, highlighting significant advancements in rare disease treatment.
Soligenix Inc. Receives FDA Orphan Drug Designation for Dusquetide in Behçet’s Disease
Soligenix Inc. has been granted FDA orphan drug designation for dusquetide, a significant step forward in treating Behçet’s Disease, highlighting the potential for new therapies in rare diseases.
Soligenix Inc. Highlighted for Innovation in Rare Disease Treatment
Soligenix Inc.'s inclusion in a NetworkNewsWire editorial highlights its HyBryte(TM) platform's potential to address the urgent need for effective therapies in rare diseases, particularly cutaneous T-cell lymphoma, showcasing a commitment to domestic innovation and support for underserved patient populations.
Soligenix Inc. Advances Rare Disease Treatment with HyBryte Platform, Highlighting Growing Need in Aging Population
Soligenix Inc. is making strides in treating cutaneous T-cell lymphoma, a rare skin cancer affecting older adults, underscoring the urgent need for innovative treatments in the face of an aging population and the prevalence of rare diseases.
Soligenix Inc. Advances in Rare Disease Therapeutics with HyBryte(TM) Platform
Soligenix Inc. (NASDAQ: SNGX) is making significant strides in the development of treatments for rare diseases, particularly with its HyBryte(TM) platform for cutaneous T-cell lymphoma, addressing a critical need for FDA-approved therapies in an underserved market.
Soligenix Inc. Advances in Treating Rare Skin Cancer with HyBryte Platform
Soligenix Inc.'s progress with its HyBryte platform for treating cutaneous T-cell lymphoma highlights the critical need for innovative therapies in addressing rare diseases among the aging population.
Soligenix Inc. Advances Treatment for Rare Behçet’s Disease with SGX945
Soligenix Inc. is developing SGX945, a promising treatment for Behçet’s disease, addressing the critical need for more effective therapies for this rare condition.
Soligenix Advances Treatment for Behçet’s Disease with New Clinical Trial
Soligenix Inc. has initiated a clinical trial for SGX945, a potential treatment for Behçet’s disease, a rare autoimmune disorder with limited treatment options, highlighting a significant step towards addressing the unmet needs of patients globally.
Soligenix Inc. Advances Clinical Programs with Key Trial Results Expected by 2026
Soligenix Inc. is making significant progress in its clinical programs, with critical trial results for treatments of rare diseases like cutaneous T-cell lymphoma and Behçet’s disease expected in the coming years, highlighting the company's role in addressing unmet medical needs.
Telomir Pharmaceuticals Reports Significant Preclinical Breakthrough with Telomir-1 in Wilson’s Disease Model
Telomir Pharmaceuticals' preclinical data reveals Telomir-1's potential to reverse symptoms of Wilson’s disease, a rare copper accumulation disorder, marking a significant step towards human trials and offering hope for patients.
Telomir Pharmaceuticals Advances Neurological Research with Novel Cellular Restoration Candidate
Telomir Pharmaceuticals reveals promising preclinical data for Telomir-1, a small molecule targeting cellular decline, with potential applications in autism spectrum disorder and rare neurological conditions. The research demonstrates potential breakthrough in understanding age-related cellular deterioration.
Soligenix CEO Highlights Rare Disease Therapeutics and Public Health Solutions Strategy
Soligenix's CEO discusses the company's two-pronged business model focused on rare disease treatments and public health solutions, emphasizing significant government funding and promising clinical trial developments.
Soligenix Advances Treatment for Rare Skin Cancer with HyBryte™ Therapy
Soligenix's HyBryte™ therapy shows promise in treating early-stage cutaneous T-cell lymphoma, potentially addressing a significant gap in rare disease treatments within a rapidly growing global market.